Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G whole PTH Assay
A 3rd Generation Assay to Accurately Measure Biologically Active Parathyroid Hormone Levels Resulting From Disorders of Calcium Metabolism MALVERN, PA. (PRWEB) NOVEMBER 20, 2019 Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA) clearance of the company’s Lumipulse® G whole PTH Assay[…]
Read more